# Cofactor Genomics

Source: https://onco.cc/companies/cofactor-genomics/  
OnCo record `cofactor-genomics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Cofactor Genomics reads the RNA of a tumour sample to model the immune cells inside it, and uses that to predict who will respond to immunotherapy.

## Summary

Cofactor Genomics builds RNA-based diagnostics using what it calls Predictive Immune Modeling: multidimensional RNA expression models of the tumour immune microenvironment trained on large datasets. Its OncoPrism assay is intended to predict response to checkpoint inhibitors, with validation work presented in head and neck and other solid tumours and analytical validation published in molecular diagnostics journals. The company is CAP and CLIA accredited and, per its YC profile, is backed by Menlo Ventures, DCVC and Ascension Ventures. Evidence is at the clinical validation stage rather than randomised proof of benefit.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- Tags: yc
- HQ: St. Louis, MO
- Type: diagnostics
- Website: https://cofactorgenomics.com

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Cofactor_Genomics
- Y Combinator profile: https://www.ycombinator.com/companies/cofactor-genomics
- Official website: https://cofactorgenomics.com

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Companion diagnostics](https://onco.cc/technologies/companion-diagnostic/), [RNA sequencing & expression profiling](https://onco.cc/technologies/rna-seq/)
- targets: [PD-1](https://onco.cc/targets/pd1/)
- companies: [Y Combinator](https://onco.cc/companies/y-combinator/)

---
JSON: https://onco.cc/api/v1/entities/cofactor-genomics.json